Clinical trials: Genital Neoplasms, Male
Prostate Cancer
PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing
The aim of this retrospective study was to assess the prognostic value of parameters extracted from 18FDG PET/CT and 68Ga-PSMA PET in the initial workup and follow-up of patients treated with 177Lu-PSMA in mCRPC.
- Trial name
- PROFLu (NCT06460454)
- Testing
- PET scan of 18F-FDG
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Prostate Cancer
Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer
The purpose of this study is to test if interleukin-2, a drug that stimulates the immune system, can be used after chemotherapy to slow the progression of your disease.
- Trial name
- NCT00283829
- Testing
- docetaxel, IL2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
Prostate Cancer
Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
This is a trial of 5 fraction SBRT combined with androgen deprivation therapy for patients with localized high-risk or unfavorable intermediate risk prostate cancer
- Trial name
- NCT04489745
- Testing
- SBRT, Androgen deprivation therapy (ADT)
- Volunteers
- 72 people
- Sponsor
- VA Greater Los Angeles Healthcare System
Prostatic Neoplasms
Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status
Prostate cancer is the most frequent cancer in Norwegian men. For optimal treatment, accurate staging of the disease at the time point of diagnosis is important.
- Trial name
- NCT02076503
- Testing
- PET-MR 18f-FACBC, histology (gold standard)
- Where
- Norway
- Volunteers
- 28 people
- Sponsor
- St. Olavs Hospital
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests how well Pluvicto works in treating African American patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that has…
- Trial name
- PluvEquity (NCT07860554)
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Emory University
Olanzapine, CINV
Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer
This study aims to investigate the efficacy and safety of olanzapine combined with fosaprepitant, ondansetron and dexamethasone compared with placebo combined with fosaprepitant, ondansetron and dexamethasone in the prevention of…
- Conditions
- Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin
- Trial name
- NCT05244577
- Testing
- Olanzapine Tablets
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Shi Yanxia
Prostate Cancer, Lower Limb Lymphedema
Risk Factors, Incidence, and Progression of Lymphedema Among Men With Prostate Cancer. The AWARE Cohort
The goal of this observational study is to examine the development and impact of lymphedema in men treated for prostate cancer. Lymphedema is swelling caused by damage to the lymphatic system and may develop after surgery with…
- Trial name
- AWARE (NCT07607431)
- Testing
- Radical Prostatectomy and Radiotherapy
- Where
- 3 sites in Denmark
- Volunteers
- 214 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Prostate Cancer
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer
The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.
- Trial name
- NCT01317641
- Testing
- ODM-201
- Where
- 23 sites in United States, Czechia and 4 more
- Volunteers
- 136 people
- Sponsor
- Orion Corporation, Orion Pharma
Prostate Cancer
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
This research study is being done to measure the clinical benefit associated with cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs (organs other than bone or lymph nodes) and no longer…
- Trial name
- NCT01834651
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Edwin Posadas, MD
Prostate Cancer
Repeatability of Positron Emission Tomography (TEP) With fluorométhyl-(18F)-diméthyl-2-hydroxyéthyl-ammonium
Monocentric study. Objective : Determination of the repeatability of fluorocholine PET/CT in prostate cancer
- Trial name
- NCT03105869
- Testing
- fluorocholine PET/CT
- Volunteers
- 20 people
- Sponsor
- Poitiers University Hospital
Prostate Cancer
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
Currently, there are no established 2nd-line or salvage chemotherapy regimens for patients with HRPC, many of whom retain an excellent performance status.
- Trial name
- NCT00545766
- Testing
- Vinflunine
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- SCRI Development Innovations, LLC
Cancer of Prostate
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Comparing the effect of switching from Lupron and Zoladex to Eligard. PSA and Testosterone levels are measured at set intervals to determine if Eligard is equal or better then Lupron or Zoladex in advanced Prostate Cancer…
- Trial name
- NCT00220194
- Testing
- leuprolide acetate
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- San Bernardino Urological Associates Medical Group Inc
Melanoma, Non-small Cell Lung Carcinoma (NSCLC)
LITT and Pembrolizumab in Recurrent Brain Metastasis
This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with…
- Conditions
- Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer
- Trial name
- TORCH (NCT04187872)
- Testing
- LITT + Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Florida
Prostate Cancer
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
This study is for patients who have been treated with surgical removal of the testes or hormone therapy (Lupron or Zoladex) and whose prostate cancer has worsened despite this treatment.
- Trial name
- NCT00183937
- Testing
- PS 341, Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Prostate Cancer
Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Combination of PSA/DRE and Multi Parametric Magnetic Resonance Imaging
This randomized prospective multi center study is designed to confirm a new diagnostic pathway in primary diagnosis of clinically significant prostate cancer by combination of serum levels of prostate specific antigen (PSA)…
- Trial name
- PRIMA (NCT04993508)
- Testing
- PSA test, multiparametric prostate Magnetic Resonance Imaging (mpMRI), targeted MRI/US fusion-guided biopsy
- Volunteers
- 1,908 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Prostatic Neoplasms
Stereotactic Radiotherapy for Oligometastatic Prostate Cancer
This is a study that assesses the safety and efficacy of using stereotactic radiotherapy in conjunction with hormone therapy for patients with metastatic prostate cancer where there are a limited number of metastatic tumours.
- Trial name
- CROP (NCT02563691)
- Testing
- stereotactic radiotherapy
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- Sunnybrook Health Sciences Centre
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer
- Trial name
- NCT04152018
- Testing
- PF-06940434, PF-06801591
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 85 people
- Sponsor
- Pfizer
Prostate Cancer
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
The study is being done to find out whether combining two FDA approved drugs along with radiation therapy for the treatment of high risk localized prostate cancer is safe and well tolerated.
- Trial name
- NCT02064582
- Testing
- Enzalutamide, Leuprolide acetate, radiation
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Texas Southwestern Medical Center
Prostate Cancer
Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer
Stage 2B: NanoTherm ablation of focal prostate cancer in small lesions in Gleason 3+4 disease. The outcome of this ablation is validated by a transperineal biopsy at 4 months after ablation.
- Trial name
- NCT05010759
- Testing
- NanoTherm Ablation
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- MagForce USA
Prostate Cancer
Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic…
- Trial name
- NCT00003626
- Testing
- dolastatin 10
- Where
- 3 sites in United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.